Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study.
<h4>Background</h4>Development of an effective antiviral drug for Coronavirus Disease 2019 (COVID-19) is a global health priority. Although several candidate drugs have been identified through in vitro and in vivo models, consistent and compelling evidence from clinical studies is limite...
Main Authors: | Shoya Iwanami, Keisuke Ejima, Kwang Su Kim, Koji Noshita, Yasuhisa Fujita, Taiga Miyazaki, Shigeru Kohno, Yoshitsugu Miyazaki, Shimpei Morimoto, Shinji Nakaoka, Yoshiki Koizumi, Yusuke Asai, Kazuyuki Aihara, Koichi Watashi, Robin N Thompson, Kenji Shibuya, Katsuhito Fujiu, Alan S Perelson, Shingo Iwami, Takaji Wakita |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-07-01
|
Series: | PLoS Medicine |
Online Access: | https://doi.org/10.1371/journal.pmed.1003660 |
Similar Items
-
Revisiting the guidelines for ending isolation for COVID-19 patients
by: Yong Dam Jeong, et al.
Published: (2021-07-01) -
A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2.
by: Kwang Su Kim, et al.
Published: (2021-03-01) -
Estimation of the incubation period of COVID-19 using viral load data
by: Keisuke Ejima, et al.
Published: (2021-06-01) -
Correction to: Required concentration index quantifies effective drug combinations against hepatitis C virus infection
by: Yusuke Kakizoe, et al.
Published: (2021-01-01) -
Required concentration index quantifies effective drug combinations against hepatitis C virus infection
by: Yusuke Kakizoe, et al.
Published: (2021-01-01)